{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:36:07Z","timestamp":1794072967950,"version":"4.8.0"},"reference-count":31,"publisher":"American Society of Hematology","issue":"9","license":[{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,29]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Patients with hemophilia A require exogenous factor VIII (FVIII) or nonfactor hemostatic agents to prevent spontaneous bleeding events. Adeno-associated virus (AAV) vector\u2013based gene therapy is under clinical investigation to enable endogenous FVIII production. Giroctocogene fitelparvovec is a recombinant AAV serotype 6 vector containing the coding sequence for the B-domain\u2013deleted human F8 gene. In the ongoing phase 1\/2, dose-ranging Alta study, 4 sequential cohorts of male participants with severe hemophilia A received a single IV dose of giroctocogene fitelparvovec. The primary end points are safety and changes in circulating FVIII activity. Interim results up to 214 weeks after treatment for all participants are presented. Eleven participants were dosed. Increases in\u00a0alanine and aspartate aminotransferases were the most common treatment-related adverse events (AEs), which resolved with corticosteroid administration. Two treatment-related serious AEs (hypotension and pyrexia) were reported in 1 participant within 6\u00a0hours of infusion and resolved within 24 hours after infusion. At the highest dose level (3\u00a0\u00d7 1013 vg\/kg; n\u00a0= 5), the mean circulating FVIII activity level at week 52 was 42.6% (range, 7.8%-122.3%), and at week 104 it was 25.4% (range, 0.9%-71.6%) based on a chromogenic assay. No liver masses, thrombotic events, or confirmed inhibitors were detected in any participant. These interim 104-week data suggest that giroctocogene fitelparvovec is generally well tolerated with appropriate clinical management and has the potential to provide clinically meaningful FVIII activity levels, as indicated by the low rate of bleeding events in the highest dose cohort. This trial was registered at www.clinicaltrials.gov as #NCT03061201.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2022018971","type":"journal-article","created":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T18:11:41Z","timestamp":1698084701000},"page":"796-806","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":48,"title":["Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1\/2 Alta\u00a0study"],"prefix":"10.1182","volume":"143","author":[{"given":"Andrew D.","family":"Leavitt","sequence":"first","affiliation":[{"name":"1University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3959-8797","authenticated-orcid":false,"given":"Barbara A.","family":"Konkle","sequence":"additional","affiliation":[{"name":"2Washington Center for Bleeding Disorders and the University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimo C.","family":"Stine","sequence":"additional","affiliation":[{"name":"3UAMS at Arkansas Children\u2019s Hospital, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Visweshwar","sequence":"additional","affiliation":[{"name":"4University of South Florida, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Harrington","sequence":"additional","affiliation":[{"name":"5University of Miami Miller School of Medicine, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Giermasz","sequence":"additional","affiliation":[{"name":"6Hemophilia Treatment Center, University of California Davis, Sacramento, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Arkin","sequence":"additional","affiliation":[{"name":"7Pfizer Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Fang","sequence":"additional","affiliation":[{"name":"8Pfizer Inc, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Plonski","sequence":"additional","affiliation":[{"name":"9Pfizer Inc, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Yver","sequence":"additional","affiliation":[{"name":"10Pfizer Inc, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Ganne","sequence":"additional","affiliation":[{"name":"10Pfizer Inc, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Agathon","sequence":"additional","affiliation":[{"name":"10Pfizer Inc, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria de los Angeles","family":"Resa","sequence":"additional","affiliation":[{"name":"8Pfizer Inc, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Jung","family":"Tseng","sequence":"additional","affiliation":[{"name":"8Pfizer Inc, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Di Russo","sequence":"additional","affiliation":[{"name":"9Pfizer Inc, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina M.","family":"Cockroft","sequence":"additional","affiliation":[{"name":"11Sangamo Therapeutics, Brisbane, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2567-5480","authenticated-orcid":false,"given":"Liching","family":"Cao","sequence":"additional","affiliation":[{"name":"11Sangamo Therapeutics, Brisbane, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Rupon","sequence":"additional","affiliation":[{"name":"9Pfizer Inc, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2024022916364218400_bib1","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/hae.13816","article-title":"Clinical advances in gene therapy updates on clinical trials of gene therapy in haemophilia","volume":"25","author":"Peyvandi","year":"2019","journal-title":"Haemophilia"},{"issue":"26","key":"2024022916364218400_bib2","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1182\/bloodadvances.2017009878","article-title":"Hemophilia gene therapy comes of age","volume":"1","author":"George","year":"2017","journal-title":"Blood Adv"},{"issue":"25","key":"2024022916364218400_bib3","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2024022916364218400_bib4","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1089\/hum.2010.155","article-title":"Safety of liver gene transfer following peripheral intravascular delivery of adeno-associated virus (AAV)-5 and AAV-6 in a large animal model","volume":"22","author":"Favaro","year":"2011","journal-title":"Hum Gene Ther"},{"issue":"12","key":"2024022916364218400_bib5","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1016\/j.ymthe.2022.10.010","article-title":"First-in-human in\u00a0vivo genome editing via\u00a0AAV-zinc-finger nucleases for mucopolysaccharidosis I\/II and hemophilia B","volume":"30","author":"Harmatz","year":"2022","journal-title":"Mol Ther"},{"issue":"1","key":"2024022916364218400_bib6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/blood-2005-12-5115","article-title":"Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs","volume":"108","author":"Jiang","year":"2006","journal-title":"Blood"},{"issue":"7","key":"2024022916364218400_bib7","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1182\/blood-2005-10-4035","article-title":"Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver","volume":"107","author":"Nathwani","year":"2006","journal-title":"Blood"},{"issue":"15","key":"2024022916364218400_bib8","doi-asserted-by":"crossref","first-page":"7711","DOI":"10.1128\/JVI.00542-08","article-title":"Biodistribution and\u00a0safety profile of recombinant adeno-associated virus serotype 6 vectors following intravenous delivery","volume":"82","author":"Stone","year":"2008","journal-title":"J\u00a0Virol"},{"issue":"6","key":"2024022916364218400_bib9","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/mt.2008.76","article-title":"Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection","volume":"16","author":"Zincarelli","year":"2008","journal-title":"Mol Ther"},{"issue":"6","key":"2024022916364218400_bib10","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum Gene Ther"},{"issue":"7-8","key":"2024022916364218400_bib11","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1089\/hum.2021.287","article-title":"Global seroprevalence of pre-existing immunity against AAV5 and other AAV serotypes in people with hemophilia A","volume":"33","author":"Klamroth","year":"2022","journal-title":"Hum Gene Ther"},{"key":"2024022916364218400_bib12","author":"Riley","year":"13, 2016"},{"key":"2024022916364218400_bib13","unstructured":"Hemgenix (etranacogene dezaparvovec-drlb). Prescribing information; 2022. US Food and Drug Administration. Accessed 23 August 2023. https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/hemgenix."},{"key":"2024022916364218400_bib14","unstructured":"Roctavain (valoctocogene roxaparvovec-rvox). Prescribing information; 2023. US Food and Drug Administration. Accessed 23 August 2023. https:\/\/labeling.cslbehring.com\/PI\/US\/Hemgenix\/EN\/Hemgenix-Prescribing-Information.pdf."},{"key":"2024022916364218400_bib15","unstructured":"European Medicines Agency\n          . Hemgenix (Etranacogene Dezaparvovec)-European Public Assessment Report (EPAR). Accessed 22 August 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/hemgenix."},{"key":"2024022916364218400_bib16","unstructured":"European Medicines Agency\n          . Roctavian [Valoctocogene Roxaparvovec]-European Public Assessment Report (EPAR). Accessed 23 August 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/roctavian-0."},{"issue":"21","key":"2024022916364218400_bib17","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2104205","article-title":"Multiyear factor VIII expression after AAV gene transfer for hemophilia A","volume":"385","author":"George","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2024022916364218400_bib18","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024022916364218400_bib19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"2024022916364218400_bib20","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-factor VIII gene transfer in severe hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2024022916364218400_bib21","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"issue":"1","key":"2024022916364218400_bib22","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.seminhematol.2015.10.002","article-title":"Gene therapy for hemophilia: past, present and future","volume":"53","author":"George","year":"2016","journal-title":"Semin Hematol"},{"issue":"23","key":"2024022916364218400_bib23","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B gene therapy with a high-specific-activity factor IX variant","volume":"377","author":"George","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2024022916364218400_bib24","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1182\/blood-2018-99-115495","article-title":"A\u00a0phase 1\/2 trial of investigational Spk-8011 in hemophilia A demonstrates durable expression and prevention of bleeds [abstract]","volume":"132","author":"High","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2024022916364218400_bib25","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2018-99-118256","article-title":"GO-8: preliminary results of a phase I\/II dose escalation trial of gene therapy for haemophilia A using a novel human factor VIII variant [abstract]","volume":"132","author":"Nathwani","year":"2018","journal-title":"Blood"},{"key":"2024022916364218400_bib26","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.omtm.2020.07.005","article-title":"Induction of ER stress by an AAV5 BDD FVIII construct is dependent on the strength of the hepatic-specific promoter","volume":"18","author":"Fong","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2024022916364218400_bib27","doi-asserted-by":"crossref","first-page":"16063","DOI":"10.1038\/mtm.2016.63","article-title":"Potential for cellular stress response to hepatic factor VIII expression from AAV vector","volume":"3","author":"Zolotukhin","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2024022916364218400_bib28","doi-asserted-by":"crossref","first-page":"16064","DOI":"10.1038\/mtm.2016.64","article-title":"Overexpression of factor VIII after AAV delivery is transiently associated with cellular stress in hemophilia A mice","volume":"3","author":"Lange","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"22","key":"2024022916364218400_bib29","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1182\/blood.2020005683","article-title":"Activity of transgene-produced B-domain-deleted factor VIII in human plasma following AAV5 gene therapy","volume":"136","author":"Rosen","year":"2020","journal-title":"Blood"},{"issue":"6","key":"2024022916364218400_bib30","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1365-2516.2011.02539.x","article-title":"Clinical severity of haemophilia A: does the classification of the 1950s still stand?","volume":"17","author":"Den Uijl","year":"2011","journal-title":"Haemophilia"},{"issue":"16","key":"2024022916364218400_bib31","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1182\/bloodadvances.2018020552","article-title":"The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B","volume":"2","author":"Soucie","year":"2018","journal-title":"Blood Adv"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/9\/796\/2216684\/blood_bld-2022-018971-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/9\/796\/2216684\/blood_bld-2022-018971-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T11:37:02Z","timestamp":1709206622000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/9\/796\/498400\/Giroctocogene-fitelparvovec-gene-therapy-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,2,29]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022018971","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,29]]}}}